Merrimack Pharmaceuticals
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$1,181,000 over the previous period. Total operating expenses were $2,176,000.

Profit Margin

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK): Profit margin
2014 102.75M -83.29M -81.06%
2015 89.25M -147.95M -165.76%
2016 144.27M -151.74M -105.18%
2017 0 472.02M
2018 0 -40.50M
2019 0 -21.26M
2020 0 -3.02M
2021 0 -2.45M
2022 0 -1.54M
2023 0 -1.18M

MACK Income Statement (2014 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue
Revenue
0000000144.27M89.25M102.75M
Cost of revenue
0445K002.22M006.91M46K0
Gross profit
0-445K00-2.22M00137.36M89.21M102.75M
Operating exp.
Research and development
000011.1M49.97M67.31M160.91M160.98M138.49M
Selling and marketing
2.17M000000000
Total operating expenses
2.17M2.17M2.61M5.01M27.26M65.57M95.76M241.64M218.58M169.01M
Operating income
-2.17M-1.72M-2.47M-2.87M-22.35M-65.57M-95.76M-110.14M-129.57M-66.25M
Other income (expenses), net
1.00M188K20K-141K-381K-3.23M-22.63M-49.23M-18.21M-17.30M
Income before tax
-1.16M-1.54M-2.45M-3.01M-22.74M-68.46M-118.40M-153.51M-147.78M-83.55M
Income tax expense
12K3K3K14K-1.47M-7.69M-42.39M-13.22M-3.91M-3.49M
Net income
-1.18M-1.54M-2.45M-3.02M-21.26M-40.50M472.02M-151.74M-147.95M-83.29M
Earnings per share
Basic EPS
-0.08-0.11-0.18-0.23-1.59-3.0435.67-12.11-13.29-7.98
Diluted EPS
-0.08-0.11-0.18-0.23-1.59-3.0435.67-12.11-13.29-7.98
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData source